A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukemia.

Trial Profile

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine; Mitoxantrone
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2009 Additional trial location (Wales) added as reported by United Kingdom Clinical Research Network record.
    • 07 Apr 2009 New source identified and integrated (United Kingdom Clinical Research Network 1087413)
    • 04 Apr 2008 Status changed from in progress to completed based on reported results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top